LogicMark, Inc.

LGMK
About the company

LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company offers Guardian Alert 911 Plus, Freedom Alert, Freedom Alert Mini, and Freedom Alert Max, which are home-based landline solutions.

Country: United StatesPrice: $1.30Market Cap: $1.2M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-10-01

Latest source filing: 2026-08-19

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30

Latest source filing: 2026-08-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Market data at 2026-10-01

Latest source filing: 2026-08-19

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-10-01

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-27

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-10-01 · Annual history · FY 2025

Latest source filing: 2026-08-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-19

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-19

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-10-01

Latest source filing: 2026-08-19

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 9✗ 19▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.1x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise ValueN/A (EV <= 0)
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-127.2%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.1x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-466.8%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-438.7%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.1x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low258% of trailing low ($0.50)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-532.37%; #5933/6340 (top 93.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+11.2792; #179/6449 (top 2.8%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.09x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+10.7243; #307/5247 (top 5.9%)
      ✓OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-349.78%; #4299/4519 (top 95.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+157.94%; #195/6202 (top 3.1%)
      ✓OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-5.5M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-5.1M
      ✗LynchPositive and growing
      Operating Cash Flow$-5.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-24.92%, ROA=-36.77%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-438.7%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/4 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-347.3%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency1/13 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-4.1M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-349.78%; #4299/4519 (top 95.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 51.1% vs Rev: 20.6%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.01 (2012) -> $-13.06 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/14 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-0.3%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency2/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 67.1% -> 66.8%, operating margin -154.4% -> -69.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR-0.0%
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts7% pass✓ 1✗ 13▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 4)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag LGMK's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities4.88
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Profitability13% pass✓ 7✗ 28▾

      14 of 16 flag LGMK's profitability — Graham, Buffett, Lynch +11 more

      Positive EPS (10 years)0/15 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/15 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-64.1%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-69.1% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-5.5M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-47.2%
      ✗Lynch> 15%
      EBIT / Enterprise ValueN/A (EV <= 0)
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-127.2%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-36.77%
      ✗PiotroskiROA > 0
      ROA Change YoY-63.31% -> -36.77% (delta: +26.54%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-24.92%, ROA=-36.77%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY66.8% -> 66.8%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-49.5%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-47.2%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.1x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-81.2% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/14 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-51.9%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-47.2%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-154.4% (2023) -> -69.1% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 67.1% -> 66.8%, operating margin -154.4% -> -69.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-532.37%; #5933/6340 (top 93.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+50.86%; #653/3702 (top 17.6%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity-47.20%; #4175/5226 (top 79.9%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.2128; #4291/5884 (top 72.9%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag LGMK's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio4.88
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-103.1%
      ✗Buffett> 10%
      ROIC - WACC-113.1%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-127.2%
      ✗Greenblatt> 25%
      Current Ratio Change YoY2.63 -> 6.00
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.70x -> 0.56x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities4.88
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($1.2M)
    Revenue: $11.4M+15.4% YoY
    Net Income: $7.5M+17.1% YoY

    Financial Snapshot

    Operating Margin-69.1%
    Return on Equity-45.9%
    Debt / Equity--
    Current Ratio6.00
    EPS (Diluted)$-13.06
    Shares Retired−42.7% / 57.9% 2y

    Shareholder Return

    Fiscal 2025

    Issued 42.7% of shares last year, 57.9% over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, depreciation amortization.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-27
    FY 2024
    Sources
    • 10-K · 2025-03-31
    FY 2023
    Sources
    • 10-K · 2024-04-16
    FY 2022
    Sources
    • 10-K · 2023-03-30
    FY 2021
    Sources
    • 10-K · 2022-04-15
    Market Cap$1.2Mcurrent----$616.1Kest.$547.7Mest.$41.9Best.$864.8Best.$9.5Test.
    Revenue$12.5M↑21%$3.3M↑17%$3.2M↑24%$11.4M↑15%$9.9M$9.9M↓17%$11.9M↑19%$10.0M
    Operating Income-$6.5M↑22%-$1.6M↑25%-$1.5M↑36%-$7.9M↓3%-$7.7M↑50%-$15.3M↓122%-$6.9M↑8%-$7.5M
    Net Income-$6.2M↑34%-$1.6M↑24%-$1.5M↑34%-$7.5M↑17%-$9.0M↑38%-$14.6M↓110%-$6.9M↑41%-$11.7M
    EPS (Diluted)--$-1.81$-1.68↓1300%$-13.06↑11%$-14.65↓26%$-11.66↓1434%$-0.76↑66%$-2.23
    Gross Margin69.1%↑5%70.7%↑5%69.6%↑10%66.8%66.8%67.1%↑11%60.7%↑5%57.7%
    Operating Margin-51.9%↑35%-47.6%↑36%-46.8%↑49%-69.1%↑11%-77.5%↑50%-154.4%↓166%-58.0%↑23%-75.3%
    ROE-47.2%↑3%——-45.9%↑47%-86.7%↑22%-111.0%↓236%-33.0%↑25%-44.0%
    Total Debt----------------
    Shareholders' Equity$13.2M↓32%$13.2M↓32%$14.8M↓30%$16.3M↑57%$10.4M↓21%$13.1M↓38%$21.0M↓21%$26.6M
    Current Ratio4.88↓35%4.88↓35%6.30↓17%6.00↑128%2.63↓33%3.92↓1%3.95↓63%10.76
    Debt / Equity————————
    Operating Cash Flow-$4.0M↑8%$83.3K↑108%-$1.6M-$5.1M↓19%-$4.3M↑1%-$4.3M↓20%-$3.6M↑39%-$5.9M
    Free Cash Flow-$4.1M$48.2K-$1.7M-$5.1M↓20%-$4.3M↑2%-$4.4M↓12%-$3.9M--

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    LGMK vs Peers — Financial Grading

    Revenue$11.4MBottom 25%
    Net Income$7.5MBottom 25%
    ROE-45.9%Bottom 25%
    D/E—
    Op. Margin-69.1%Bottom 25%
    Curr. Ratio6.00Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11